Semax
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Semax is listed as nootropic / neuroprotective.
- •Cognitive enhancement
- •Stroke recovery
- •Neuroprotection
- •ADHD (off-label)
Regulatory status: Approved in Russia; not FDA-approved.
Structure & Properties
Compound: Semax; also known as ACTH(4-10) analog.
Pharmacologic class: Nootropic / Neuroprotective.
Known delivery routes: Intranasal.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
ACTH analog — increases BDNF, NGF, and VEGF expression; enhances dopaminergic/serotonergic tone; neuroprotective via anti-apoptotic mechanisms.
- •Improved memory and focus
- •Stroke recovery support
- •Mood modulation
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Russian approved drug; limited Western peer review
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Intranasal, 1–2× daily in the morning or before focus-heavy tasks. Avoid late-evening dosing — may impair sleep in sensitive users.
Potential interactions and combinations to avoid
- •Stimulants (high-dose caffeine, amphetamines) — additive dopaminergic load
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Mild hypertension
- •Limited Western long-term data
Contraindications
- •Uncontrolled hypertension
- •Pregnancy
- •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- •Bipolar disorder, psychosis, or active mania
- •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- •Recent intracranial haemorrhage or unstable neurologic injury
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 300–900 mcg/day
Frequency: Once or twice daily
Cycling: 2–4 weeks on / 2 weeks off.
Intranasal
Standard — 0.1% or 1% solution.
Nasal spray or dropper. 2–3 drops per nostril AM, optionally midday. Avoid evenings.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Selank for anxiolytic balance
- •Cerebrolysin for neuro-recovery
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Morning — intranasal; avoid evening use as it can be mildly stimulating.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Intranasal — Alternate nostrils, spray on inhalation, do not sniff hard.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
2–4 weeks on / 2 weeks off.
Timing & Interactions
- ·Stimulants (high-dose caffeine, amphetamines) — additive dopaminergic load
- ·Selank for anxiolytic balance
- ·Cerebrolysin for neuro-recovery
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Semax and sync them to Vial Lab.
Benefits
- ·Improved memory and focus
- ·Stroke recovery support
- ·Mood modulation
Risks
- ·Mild hypertension
- ·Limited Western long-term data
Contraindications
- ·Uncontrolled hypertension
- ·Pregnancy
- ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- ·Bipolar disorder, psychosis, or active mania
- ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- ·Recent intracranial haemorrhage or unstable neurologic injury
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Approved in Russia; not FDA-approved
Veterinary Use (Pets)
No established veterinary protocol for Semax. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.